Company intelligence / Profile preview
Eclipse Life Sciences
Research Triangle Park, North Carolina, United Stateseclipselifesciences.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Eclipse Life Sciences is currently conducting the BETTIS-1 Phase 2 clinical trial for EC-104, a novel intravitreal corticosteroid implant with 6-month durable drug release for treating diabetic macular edema. The first patient was enrolled and dosed in August 2024. The trial is designed as a randomized, controlled, double-masked study comparing two doses of EC-104 to Ozurdex in DME patients with prior suboptimal response to anti-VEGF therapy[2][5][8].
- Therapeutic areas
- EndocrinologyOphthalmology
- Modalities
- Small moleculescorticosteroid implantsintravitreal drugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Eclipse Life Sciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eclipse Life Sciences.